Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Editas Medicine Inc Logo

ARKK Holdings of Editas Medicine (EDIT) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
January 26, 2022SELL1.220m0.1948%ARKK
January 25, 2022SELL113.400k0.017%ARKK
January 24, 2022SELL231.085k0.0339%ARKK
January 21, 2022SELL306.722k0.0452%ARKK
January 20, 2022SELL159.694k0.0259%ARKK

Key Statistics

Upcoming EarningsSee Full Calendar
DateFebruary 23, 2022(Est)Revenue
Expected$4.28m
Actual▫️
EPS
Expected-$0.72
Actual▫️
🕵🏼Found In🏷Last Price
ARKGARKK$18.58
⚖️Weighting🧢Market Cap
0.04%$1.27b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
3951.88
🏋️‍♀️Weight Rank Across All Funds🌏Country
115🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$29.070.34%
Description
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Website
www.editasmedicine.com

Research Notes and Commentary for EDIT